Skip to main content

Table 2 Pathway over-representation analysis using the 232 genes for which the 251 probes showing pre-afatinib cell-free DNA (cfDNA) methylation profiles correlated with progression-free survival (PFS) are designed, based on the protein analysis using the evolutionary relationships database (version 18.0, https://www.pantherdb.org) (P < 0.05 and false discovery rate [FDR] < 0.1)

From: Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

ID

Description

P

FDR

Genes for which cfDNA methylation status was correlated with PFS and are involved in the pathway

P00012

Cadherin signaling pathway

2.06 × 10–4

2.43 × 10–3

PCDHGA2, PCDHGB2, PCDHGA1, PCDHGB1, CDH6, CTNNA2, PCDHGA5, PCDHGA3

P00057

Wnt signaling pathway

2.21 × 10–4

2.43 × 10–3

PCDHGA2, PCDHGB2, PCDHGA1, PCDHGB1, CDH6, NKD2, CTNNA2, SMARCA2, PLCB4, PCDHGA5, PCDHGA3

P00018

EGF receptor signaling pathway

2.05 × 10–3

1.51 × 10–2

PIK3C2A, PIK3R6, CCM2, PLCB4, TGFA, PHLDB2

P00019

Endothelin signaling pathway

1.05 × 10–2

5.76 × 10–2

PRKG1, PIK3C2A, PIK3R6, PLCB4

P00060

Ubiquitin proteasome pathway

1.91 × 10–2

7.33 × 10–2

PSMD6, WWP1, UBE2H

P04391

Oxytocin receptor mediated signaling pathway

2.00 × 10–2

7.33 × 10–2

PLCB4, CACNA1C, CACNA1D

P04374

5HT2 type receptor mediated signaling pathway

2.78 × 10–2

8.75 × 10–2

PLCB4, CACNA1C, CACNA1D